Clinical Trials results for "relapsed acute lymphoblastic leukemia"

Showing 1-6 of 6 items
1.
  • Abatacept as GVHD Prophylaxis Phase 2
  • This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections. Funding Source - FDA OOPD
  • Diagnoses: Pediatric Hematopoietic Stem Cell Transplant (HSCT)
  • Status: Recruiting
2.
3.
4.
5.
  • Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
  • This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.
  • Diagnoses: Pediatric Leukemia
  • Status: Recruiting
6.
  • Matched Targeted Therapy For High-Risk Leukemias
  • This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.
  • Diagnoses: Pediatric Leukemia
  • Status: Recruiting
Showing 1-6 of 6 items

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
We can help you navigate your options.

Get Clinical Trial Updates

 

Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.

Download Our Clinical Trials

Download a list of our open clinical trials. Check back regularly for updates.